Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation

Sitagliptin to Prevent Acute Graft-versus-Host Disease

(2021) Paul J. Martin   NEW ENGLAND JOURNAL OF MEDICINE

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy

(2020) Laura A. Vitale et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

T cell costimulation, checkpoint inhibitors and anti-tumor therapy

(2020) Dipankar Nandi et al.   JOURNAL OF BIOSCIENCES

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

(2020) John Kuruvilla et al.   JOURNAL OF CLINICAL ONCOLOGY

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

(2020) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Source and Dynamics of Adult Hematopoiesis: Insights from Lineage Tracing

(2020) Joseph N. Pucella et al.   Annual Review of Cell and Developmental Biology

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency

(2020) Sujal Ghosh et al.   BLOOD

Donor monocyte–derived macrophages promote human acute graft-versus-host disease

(2020) Laura Jardine et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies

(2020) Stephen M. Ansell et al.   Blood Advances

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

(2019) Patrick A. Ott et al.   CANCER

CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen

(2019) Kelly A. Remedios et al.   JOURNAL OF IMMUNOLOGY

Frontline Science: Late CD27 stimulation promotes IL‐7Rα transcriptional re‐expression and memory T cell qualities in effector CD8 + T cells

(2019) Han Dong et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

(2019) Virginia Escamilla Gómez et al.   BONE MARROW TRANSPLANTATION

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+T-Cell–Driven Antitumor Immunity

(2018) Sarah L. Buchan et al.   CLINICAL CANCER RESEARCH

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

(2018) Michael D Jain et al.   Therapeutics and Clinical Risk Management

Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia

(2018) Francesco Saraceni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.

(2018) Rachel E. Sanborn et al.   JOURNAL OF CLINICAL ONCOLOGY

CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response

(2018) Katherine A. Riccione et al.   OncoImmunology

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity

(2018) Meinolf Thiemann et al.   Frontiers in Oncology

Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT

(2018) Yoshihiro Inamoto et al.   BONE MARROW TRANSPLANTATION

ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS

(2018) David Reardon et al.   NEURO-ONCOLOGY

MDSC; the Most Important Cell You Have Never Heard Of

(2018) R.J. Tesi   TRENDS IN PHARMACOLOGICAL SCIENCES

RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

(2018) Sean H. Lim et al.   Trials

T Cell–Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses

(2017) Rachel E. O’Neill et al.   JOURNAL OF IMMUNOLOGY

CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy

(2017) Anna Wasiuk et al.   JOURNAL OF IMMUNOLOGY

Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function

(2017) Nicholas D. Leigh et al.   JOURNAL OF IMMUNOLOGY

Purification of hematopoietic stem cells from bone marrow

(2016) Chen Tian et al.   ANNALS OF HEMATOLOGY

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years

(2016) Areej El-Jawahri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Alloantigen presentation and graft-versus-host disease: fuel for the fire

(2016) M. Koyama et al.   BLOOD

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination

(2016) T. Ahrends et al.   CANCER RESEARCH

Immunological properties of bone marrow microenvironment 1 year after allogeneic hematopoietic stem cell transplantation

(2016) Agnieszka Ciomber et al.   EXPERIMENTAL HEMATOLOGY

Fight or flight

(2015) Ben A. Croker et al.   CURRENT OPINION IN HEMATOLOGY

CD70: An emerging target in cancer immunotherapy

(2015) J. Jacobs et al.   PHARMACOLOGY & THERAPEUTICS

Missing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in Childhood

(2015) Miriam Erlacher et al.   Frontiers in Pediatrics

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

(2015) Venky Ramakrishna et al.   Journal for ImmunoTherapy of Cancer

Acute graft-versus-host disease: a bench-to-bedside update

(2014) S. G. Holtan et al.   BLOOD

The immune checkpoint inhibitors: where are we now?

(2014) Rachel M. Webster   NATURE REVIEWS DRUG DISCOVERY

Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody

(2013) Ryo Hatano et al.   BRITISH JOURNAL OF HAEMATOLOGY

CD70 Is Downregulated by Interaction with CD27

(2013) M. Kuka et al.   JOURNAL OF IMMUNOLOGY

CD8+ T Cells Produce the Chemokine CXCL10 in Response to CD27/CD70 Costimulation To Promote Generation of the CD8+ Effector T Cell Pool

(2013) V. Peperzak et al.   JOURNAL OF IMMUNOLOGY

CD26-mediated co-stimulation in human CD8+T cells provokes effector function via pro-inflammatory cytokine production

(2012) Ryo Hatano et al.   IMMUNOLOGY

CD8+T Cells: GITR Matters

(2012) Simona Ronchetti et al.   TheScientificWorldJOURNAL

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need

(2011) Avichai Shimoni et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia

(2011) Joris M. van Montfrans et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Role of CD27/CD70 pathway of activation in immunity and tolerance

(2010) Julie Denoeud et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD27 is a thymic determinant of the balance between interferon-γ- and interleukin 17–producing γδ T cell subsets

(2009) Julie C Ribot et al.   NATURE IMMUNOLOGY